New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russian |
| Publicado em: |
IMA PRESS LLC
2021-10-01
|
| Colecção: | Научно-практическая ревматология |
| Assuntos: | |
| Acesso em linha: | https://rsp.mediar-press.net/rsp/article/view/3072 |